<DOC>
	<DOCNO>NCT02400242</DOCNO>
	<brief_summary>This phase 1a/1b , multicenter , single-arm , open-label , dose escalation study determine maximum tolerate dose ( MTD ) evaluate safety preliminary antitumor activity ACY-241 oral administration monotherapy combination therapy orally administer pomalidomide low-dose dexamethasone eligible patient relapse relapsed-and-refractory multiple myeloma ( MM ) .</brief_summary>
	<brief_title>Study ACY-241 Alone Combination With Pomalidomide Dexamethasone Multiple Myeloma</brief_title>
	<detailed_description>During phase 1a , patient receive 1 cycle ACY-241 monotherapy . Patients complete ACY-241 monotherapy cycle without dose limit toxicity ( DLT ) clinically stable may continue phase 1b combination therapy , begin Cycle 2 . During phase 1b , patient receive ACY 241 combination pomalidomide low dose dexamethasone currently approve pomalidomide dose schedule . Each cohort patient phase 1a phase 1b consist least 3 patient . The first patient enrol cohort phase 1a observe 1 week enrollment subsequent patient cohort . Patients withdraw consent enter phase 1b replace . ( Replacement patient must complete phase 1a prior continue phase 1b . ) Patients experience DLT unacceptable toxicity Cycle 1 phase 1a monotherapy Cycle 2 , first cycle phase 1b combination therapy , remove study treatment . An assessment safety treatment complete Safety Review Committee ( SRC ) prior dose-escalation .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Key Must document diagnosis MM relapse relapsedandrefractory disease . All patient must relapse achieve least stable disease ( SD ) least 1 cycle treatment least 1 prior regimen develop progressive disease ( PD ) . Relapsedandrefractory patient also document evidence PD within 60 day complete last treatment Must undergone prior treatment least 2 cycle lenalidomide least 2 cycle proteasome inhibitor unless candidate . May undergone prior treatment pomalidomide patient refractory pomalidomide previously achieve response MR good pomalidomide . Must measurable disease ( serum Mprotein urine Mprotein ) . Must Eastern Cooperative Oncology Group ( ECOG ) Performance score 0 , 1 , 2 . Must able take lowdose aspirin , low molecular weight heparin , equivalent antithrombotic anticoagulant daily prophylactic anticoagulation . Key Prior therapy pomalidomide best response PD SD . Prior therapy histone deacetylase ( HDAC ) inhibitor . Any following laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1,000/µL , Platelet count &lt; 75,000/µL &lt; 50,000/µL patient ≥ 50 % bone marrow nucleate cell plasma cell , Hemoglobin &lt; 8 g/dL , Creatinine clearance &lt; 45 mL/min accord CockcroftGault formula . If creatinine clearance calculate 24 hour urine sample ≥ 45 mL/min , patient qualify trial , Aspartate transaminase ( AST ) Alanine transaminase ( ALT ) &gt; 3.0 × Upper Limited Normal ( ULN ) , Serum total bilirubin &gt; 2.0 mg/dL &gt; 3.0 × ULN patient hereditary benign hyperbilirubinaemia . Hematologic growth factor allow screen first cycle phase 1a 1b . Nonsecretory myeloma free light chain detect serum ( ogliosecretory ) . Hypersensitivity thalidomide , lenalidomide , pomalidomide , dexamethasone Patients receive allogeneic bone marrow allogeneic peripheral blood stem cell transplant le 12 month prior initiation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>